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Abstract
Background:  After peripheral nerve injury, spontaneous ectopic activity arising from the
peripheral axons plays an important role in inducing central sensitization and neuropathic pain.
Recent evidence indicates that activation of spinal cord microglia also contributes to the
development of neuropathic pain. In particular, activation of p38 mitogen-activated protein kinase
(MAPK) in spinal microglia is required for the development of mechanical allodynia. However,
activity-dependent activation of microglia after nerve injury has not been fully addressed. To
determine whether spontaneous activity from C- or A-fibers is required for microglial activation,
we used resiniferatoxin (RTX) to block the conduction of transient receptor potential vanilloid
subtype 1 (TRPV1) positive fibers (mostly C- and Aδ-fibers) and bupivacaine microspheres to block
all fibers of the sciatic nerve in rats before spared nerve injury (SNI), and observed spinal microglial
changes 2 days later.
Results: SNI induced robust mechanical allodynia and p38 activation in spinal microglia. SNI also
induced marked cell proliferation in the spinal cord, and all the proliferating cells (BrdU+) were
microglia (Iba1+). Bupivacaine induced a complete sensory and motor blockade and also
significantly inhibited p38 activation and microglial proliferation in the spinal cord. In contrast, and
although it produced an efficient nociceptive block, RTX failed to inhibit p38 activation and
microglial proliferation in the spinal cord.
Conclusion: (1) Blocking peripheral input in TRPV1-positive fibers (presumably C-fibers) is not
enough to prevent nerve injury-induced spinal microglial activation. (2) Peripheral input from large
myelinated fibers is important for microglial activation. (3) Microglial activation is associated with
mechanical allodynia.
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Background
Injuries to peripheral nervous system can result in neuro-
pathic pain and contribute to chronic post-operative pain
[1]. Current treatments for persistent post-operative pain
are not satisfactory and prevention at early stage might be
important for the success [2]. Section of a peripheral nerve
induces injury discharges at the time of injury followed by
spontaneous activity in the axons and soma of primary
sensory neurons. The onset of spontaneous activity is
strongly implicated in the generation of neuropathic pain
[3-6]. However, the relative contribution of different types
of primary afferents to the genesis of spontaneous activity
is still under debate. Many studies demonstrated that A-
fibers are the principal contributors of ectopic firing from
the periphery following nerve injury [7-11]. Some studies
also reported spontaneous activity in C-fibers but at differ-
ent times after nerve injury, either very early during the
first 15 minutes [12] or later after a few days [13]. The C-
fibers' activity was also found in the neighbouring intact
spinal nerve after spinal nerve ligation [5] or after stimu-
lation of a nerve stump with nociceptive mediators [14].
Interestingly, Sun et al. demonstrated a strong correlation
between ectopic discharges and pain related behavior at
the early but not late phase of nerve injury [15].
Increasing evidence suggests that spinal microglia play an
important role in neuropathic pain sensitization [16-18].
Microglia comprise around 5-20% of the glial cells and are
of monocytic origins therefore sharing many molecular
markers with macrophages. Microglial activation is
described in various ways, such as changes in morphology
(from ramified to amoeboid), gene expression (e.g., MCH
I and II, CD 11b, Iba1), function (phagocytosis), or
number (proliferation) [19]. Microglial proliferation is
rarely seen in the resting or surveying state [20] but dra-
matically increases after nerve injury [21,22]. Recent stud-
ies have also shown that (1) nerve injury activates p38
mitogen-activated protein kinase (MAPK) in spinal micro-
glia, (2) spinal infusion of p38 inhibitor attenuates neu-
ropathic pain symptoms such as mechanical allodynia
[16,23,24], and (3) blocking peripheral activity from the
site of injury with bupivacaine microspheres prevents but
does not reverse p38 activation in spinal microglia after
spared nerve injury [25].
The side effects of long-term and complete nerve block,
such as motor impairment, cannot be tolerated in
patients. Therefore the concentration of local anesthetics
is often reduced to block nociceptive fibers in the postop-
erative phase. Long-term and selective blockade of nocic-
eptive fibers is attractive and can be achieved using the
sodium channel blocker QX-314 combined with capsai-
cin [26] or resiniferatoxin (RTX), an ultrapotent agonist
for transient receptor potential vanilloid subtype-1
(TRPV1) that is only expressed in nociceptors [27,28].
Nociceptive-specific block can provide analgesia without
affecting motor function or pain-unrelated sensory func-
tion [29,30]. Recently electrical stimulation at C-fiber
intensity has been shown to induce microglial changes
[31], but it is unclear whether blocking nociceptive fibers
alone would suppress spinal microglial activation after
nerve injury. We set out to compare the effects of a general
block using bupivacaine-loaded microspheres with a
selective block of nociceptors using RTX on microglial
activation in the spared nerve injury (SNI) model of neu-
ropathic pain. To examine microglial activation, we inves-
tigated p38 activation and cell proliferation in the spinal
cord.
Methods
Animals
Experiments were done on Sprague-Dawley rats (Charles
River, MA, USA), weighing 220-250 grams. Rats were
housed in the same room at constant temperature and a
12/12 dark/light cycle and had ad libitum access to water
and food. The Harvard Medical School Animal Care Com-
mittee approved all animal procedures in this study.
Drugs
5-bromo-2-deoxyuridine (BrdU) was purchased from
Sigma, and prepared at a concentration of 20 mg/ml in
0.007 N NaOH and 0.9% NaCl [21]. Resiniferatoxin was
purchased from Sigma and dissolved in dimethyl sulfox-
yde (DMSO, 1 mg/ml) and the final concentration was
0.01% with 0.3% Tween 80, 10% DMSO, and 0.9% NaCl.
The bupivacaine-loaded microspheres were kindly pro-
vided by Dr. Charles Berde from Children's Hospital, Har-
vard Medical School. The microsphere solution
contained: 75% wt/wt bupivacaine, 24.95% wt/wt poly-
lactic-coglycollide polymer, and 0.05% wt/wt dexametha-
sone [32].
Surgery, nerve block, and group assignment of animals
Nerve block with bupivacaine microspheres: This proce-
dure was performed as previously described [32]. Rats
were anesthetized with 1.5-3.0% isoflurane, and the skin
was incised from the left greater trochanter to the knee.
The muscle layers were separated between the gluteus
superficialis and the biceps femoralis, exposing the sciatic
nerve from the emergence of the musculocutaneous
branch to the trifurcation in sural, tibial, and peroneus
branches. A silicone tube (11 mm long) was placed care-
fully around the sciatic nerve proximally from the trifurca-
tion. Two 6-0 silk ligatures were attached around the tube
to close the longitudinal slit. To facilitate the second sur-
gery for nerve injury (see below), the common peroneal
and tibial nerves were exposed and a 6-0 silk suture was
passed under each nerve and left in place. A fibrin glue
plug was placed at the distal end of the tube (Tissucol;
Baxter, Volketswil, Switzerland), and 80 μl of solutionMolecular Pain 2009, 5:53 http://www.molecularpain.com/content/5/1/53
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containing microspheres loaded with 75% w/w bupi-
vacaine (300 mg/ml) mixed in Tissucol (Baxter, Volket-
swil, Switzerland) fibrin sealant were then slowly poured
inside the tube through the proximal end which was
closed with glue. Muscle and skin were then closed in two
layers, and the animals were allowed to recover. The con-
trol group had the same surgery except that sealant with-
out bupivacaine-containing microspheres was inserted
into the silicone tube.
Nerve block with resiniferatoxin (RTX): The sciatic nerve
was exposed as previously described, and RTX solution
(0.01%, 100 μl) was perineurally injected, followed by
spared nerve injury (see below). The RTX concentration
(0.01%) was based on a previous study showing that
0.01% RTX can produce thermal blockade for 2 days [33].
Control animals had the same surgery but received
perineural injection of vehicle (0.3% Tween 80, 10%
DMSO, and 0.9% NaCl).
Spared nerve injury: This surgery was performed at least 3
hours after bupivacaine or RTX block and after sensory/
motor and radiant heat testing. The skin and muscles were
reopened at the same wound. The sutures previously
placed around common peroneal and tibial nerves were
tightened and both nerves were cut with a 1-2 mm nerve
segment was removed as previously reported [34]. Muscle
and skin were closed in two layers. Special care was taken
to avoid any damage to the sural nerve in all surgical pro-
cedures.
Animals were randomly assigned into 7 groups: (1) con-
trol group: including vehicle control for RTX injection (n
= 3) and tube insertion control (without microsphere, n =
3), and these two groups were combined into one group
(n = 6) in behavioral studies, since no differences were
found between them. (2) bupivacaine alone group (tube
with bupivacaine microspheres, no SNI, n = 3), (3) RTX
alone group (no SNI, n = 5), (4) SNI group (with tube and
SNI, without microsphere, n = 5), (5) SNI-vehicle group
(n = 5), (6) SNI-bupivacaine group (tube with micro-
spheres, n = 5), and (7) SNI-RTX group (n = 9).
Behavioral testing
Motor and sensory conduction block testing: Rats were
gently held with a cloth wrapped above their waist to
restrain upper extremities, and several measurements
were performed on both hind limbs. (1) Nociceptive
response. The skin on both sides of the hind paws (sural
and saphenous nerve territories) was pinched with a small
forceps and the withdrawal reflex response (yes or no) was
noted [35]. (2) Proprioception and motor function. Two
additional tests were used to ensure that proprioceptive
and motor functions were blocked. Briefly, hopping
response is the ability of the animals, while standing on
one leg with their body being moved laterally, to hop in
the direction of the movement (score: 0 = no hopping, 1
= successful hopping). The tactile placing response shows
the capability to reposition the paw after extension (1-4
score range: 1 is complete repositioning, 4 is no reposi-
tioning, and 2 and 3 are intermediate positions) [32,36].
All tests were performed before SNI as baseline, then on
day 1 and day 2 after SNI.
Pain assessment: Baseline behavioral testing was made
after 3 days of habituation to the environment and
observer. To avoid the effect of the circadian cycle, all
behavioral assessments were performed during the same
period (08:00-11:00 AM). The investigator was not aware
of the treatment applied. Treated and control animals
were tested during the same session. Two baselines were
taken before surgery then the animals were tested on day
1 and day 2 after SNI. To test mechanical sensitivity, ani-
mals were individually placed in a chamber on an ele-
vated metal mesh floor and allowed to acclimate for 20
minutes before testing. Light mechanical stimuli were
applied to the sural territory of a foot with a serie of von
Frey monofilaments of logarithmically incrementing stiff-
ness ranging from 0.06 g to 15 g, starting with a 2 g fila-
ment. The 50% paw withdrawal threshold (PWT) was
determined using Dixon's up-down method [37]. Each fil-
ament was applied for 5 seconds and a brisk paw with-
drawal was taken as positive response. To test heat
sensitivity, rats were placed in a plexiglas chamber on a
glass shelf. A movable radiant heat was used to stimulate
the lateral part of the hind paw, and paw withdrawal
latency was determined [38]. The intensity of radiant heat
was adjusted to elicit a response of 10-12 s latency in nor-
mal rats (baseline) and a cut-off latency (20s) was set to
avoid paw injury.
Immunohistochemistry
To label newly synthesized DNA, 5-bromo-2-deoxyurid-
ine (BrdU, 100 mg/kg) was intraperitoneally injected after
behavioral testing on SNI day 2. Two hours after BrdU
injection animals were terminally anesthetized with iso-
flurane and transcardially perfused with phosphate buffer
saline (PBS) at room temperature followed by 4% para-
formaldehyde with 1.5% picric acid in phosphate buffer
(pH 7.4, 4°C). The L4 and L5 spinal cord segments were
dissected, postfixed overnight in the same fixative, and
then transferred to 15% sucrose PBS for cryoprotection.
Spinal cord segments were frozen at -20°C in a cryostat
and transverse free-floating sections (30 μm) were cut and
collected in phosphate buffer.
For BrdU staining, spinal cord sections were first heated in
a formamide solution containing 50% formamide, 50%
2× saline sodium citrate (2 × SSC: 175.3 g NaCl; 88.2 g
sodium citrate in 1000 ml dH2O) for 2 h at 65°C to dena-Molecular Pain 2009, 5:53 http://www.molecularpain.com/content/5/1/53
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ture DNA. The sections were then washed 2 × 15 min in
2× SSC. To break any remaining hydrogen bonds between
the nitrogenous bases of nucleic acids, sections were
heated at 37°C for 30 min in 2N HCl and placed in a 0.1
M borate buffer at pH 8.5 and rinsed 3 × 10 min in Tris
buffered saline (TBS, pH 7.5). Sections were then blocked
with TBS containing 0.25% Triton X-100, 1% bovine
serum albumine and 3% normal goat serum for 1 h at
room temperature and incubated overnight with a mouse
monoclonal antibody against BrdU (1:500, Chemicon,
Temecula, CA) followed by a goat anti-mouse secondary
antibody (1:400, Jackson ImmunoResearch Inc., West
Grove, PA) for 1 hour at room temperature.
To determine if BrdU was only incorporated by microglia,
we performed double immunofluorescence by combining
mouse BrdU antibody with a rabbit antibody against the
microglial marker ionised calcium binding adapter mole-
cule 1 (Iba1, 1:500, WAKO) followed by a mixture of goat
anti-mouse fluorescein isothiocyanate- (FITC-) and goat
anti-rabbit Cy3-conjugated secondary antibodies.
For phosphorylated p38 (p-p38) staining, spinal sections
were blocked with 2% goat serum in PBS containing 0.3%
Triton and 0.01% NaN3. We incubated the sections over-
night at 4°C degrees with rabbit primary antibody
directed against phospho-p38 (rabbit, 1:500, Cell Signal-
ing Technology, Beverly, MA). The sections were then
incubated with goat anti-rabbit Cy3-conjugated second-
ary antibodies (1:400, Jackson ImmunoResearch Inc.,
West Grove, PA) for 1 hour at room temperature.
The stained sections were examined under a Nikon fluo-
rescence microscopy (Tokyo, Japan), and images were
captured with a CCD camera (SPOT, Diagnostic Instru-
ments, USA). To obtain high-resolution images of micro-
glia and confirm the double staining, confocal images
were captured with a Zeiss LSM 510 META upright confo-
cal microscope.
Quantification
To quantify BrdU- and p-p38-positive cells in the spinal
cord, 5-8 non-adjacent sections from the L4-L5 spinal
cord segment of each rat were randomly selected, and the
number of positive cells in the medial dorsal horn (lami-
nae I-III), captured under 20× object in a box (450 × 338
μm) were counted. The examiner was unaware of the
group treatment.
Statistics
All the data were presented as mean ± SEM. Two-way
ANOVA was used to assess behavioral changes over time
and between treatments. Student's t-test was used to com-
pare groups at SNI day 2. One-Way ANOVA and t-test
were used to assess differences between groups for the
number of p-p38 and BrdU immunoreactive cells. Signif-
icance level was set at p < 0.05.
Results
Different effects of bupivacaine and RTX on nociception, 
motor function, and proprioception
In animals receiving nerve blockade with bupivacaine
microspheres, we saw impairment in performing the hop
and flip test and absence of response to pinch in the sural
territory. However, RTX-treated animals showed a normal
sensory/motor behavior in the hop, flip and pinch test.
After SNI surgery motor function was disrupted, as indi-
cated by impairment in the hop and flip test but the sen-
sitivity to pinch was preserved. In SNI animals the
sensitivity to pinch in the sural territory was lost after
bupivacaine block but preserved in the RTX-treated ani-
mals. Control animals showed a normal sensory/motor
behavior in the flip, hop and pinch test. The sensitivity to
pinch in the saphenous territory was preserved in all
groups (Table 1).
RTX blocks heat sensitivity but not mechanical allodynia 
after SNI
Two days after SNI, we observed a decrease of paw with-
drawal latency to heat stimulation. The latency dropped
from 10.4 s before surgery to 7.5 s (p < 0.01) in the SNI-
Table 1: Effects of bupivacaine microspheres and RTX on nociception, motor function, and proprioception.
Hop Flip Pinch (sural) Pinch (saphenous)
Normal Blocked Normal Blocked Normal Blocked Normal Blocked
C o n t r o l  ( n  =  6 ) 60606060
R T X  o n l y  ( n  =  5 ) 50505050
B u b  o n l y  ( n  =  3 ) 03030330
SNI+vehicle (n = 10) 0 10 0 10 10 0 10 0
S N I + R T X  ( n  =  9 ) 09099090
S N I + B u p  ( n  =  5 ) 05050550
Nociceptive response was tested by pinching the hind paws in the sural and saphenous nerve territories. Proprioception and motor function were 
examined by checking hopping and flipping responses.Molecular Pain 2009, 5:53 http://www.molecularpain.com/content/5/1/53
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tube group and 7.9 s (p < 0.05) in the SNI-vehicle group.
Bupivacaine completely blocked heat response in all ani-
mals (with or without nerve injury) (Fig. 1A). RTX
increased the paw withdrawal latency in both RTX-alone
and SNI+RTX groups, compared to baseline and SNI-vehi-
cle groups (p < 0.05) (Fig. 1B).
Two days after SNI, animals in the SNI-tube and SNI-vehi-
cle groups also developed mechanical allodynia with a
reduction of paw withdrawal thresholds from 10.2 and
12.5 g to 1.98 and 0.70 g, respectively (p < 0.01). In the
bupivacaine (Bup)-treated groups (SNI+Bup) and Bup
alone), the maximal value (15 g) was reached, indicating
a complete blockade (Fig. 2A). In sharp contrast, RTX did
not change the withdrawal threshold in animals without
SNI (10.9 g vs 9.1 g, p > 0.05). Neither did RTX affect the
development of mechanical allodynia in the SNI animals
(Fig. 2B).
SNI induces proliferation of microglia in the spinal cord
To examine SNI-induced cell proliferation, we carried out
bromodeoxyuridine (BrdU) immunostaining in the spi-
nal cord. Two days after SNI, we observed a dramatic
increase in the number of BrdU-positive cells in the dorsal
horn of the spinal cord on the ipsilateral side of the nerve
injury (53.8 ± 4.3), compared to that of the contralateral
side (1.4 ± 0.3, p < 0.001) (Fig. 3A). Remarkably, almost
all BrdU positive cells were colocalized with Iba1, a micro-
glial marker (Fig. 3B-D). High-resolution images from
confocal microscopy further confirmed that BrdU was
only expressed in microglia (Fig. 4).
Bupivacaine but not RTX inhibits microglial proliferation 
after SNI
In the control group without SNI, there were only very few
BrdU-positive cells in the dorsal horn (1.1 ± 0.1 for the
tube control, and 2.4 ± 0.6 for the vehicle control, Fig. 5).
Two days after SNI, there were 40.4 ± 2.1 and 53.8 ± 4.3
BrdU-positive cells in the vehicle and tube control group,
respectively. RTX had no effect on SNI-induced microglial
proliferation. The numbers of BrdU-positive cells in the
SNI+RTX group (48.6 ± 4.3) and in the SNI-vehicle group
(53.8 ± 4.3) were comparable (p = 0.51). In contrast,
bupivacaine significantly inhibited microglial prolifera-
tion: the number of BrdU-positive cells in the SNI+Bup
group and SNI-tube group was 24.5 ± 3.7 and 40.4 ± 2.1,
respectively (n = 3, p < 0.05) (Fig. 5). RTX alone induced
a slight but significant increase, from 2.4 ± 0.6 to 8.0 ± 0.8,
in the number of BrdU-positive cells (p < 0.01). This
increase may result from a mild nerve injury caused by
RTX application.
Bupivacaine but not RTX reduces p38 activation in the 
spinal cord after SNI
To investigate the SNI-induced activation of p38 MAPK in
the spinal cord, we performed immunofluorescence using
a phosphorylated-p38 (p-p38) antibody. Two days after
SNI, a marked p38 activation was found in the dorsal
horn of the spinal cord, and the number of p-p38-positive
cells was 50.8 ± 1.5 in the SNI-vehicle group (vs 20.3 ± 2.2
in the control group, p < 0.0001) and 50.9 ± 0.7 in the
SNI-tube group (vs 12.9 ± 2.3 in the control group, p <
0.0001) (Fig. 6). RTX had no effect on SNI-induced p-p38
increase: the numbers of p-p38-positive cells in the SNI-
RTX group (56.6 ± 3.0) and in the SNI-vehicle group (50.8
± 1.5) were comparable (p = 0.25). However, bupivacaine
treatment markedly inhibited p38 activation, and the
number of p-p38-positive cells decreased from 50.9 ± 0.7
in the SNI-tube group to 35 ± 1.7 in the SNI+Bup group
(n = 3, p < 0.01). The Bup alone group also showed a mild
but significant increase in p38 activation compared to the
control group (p < 0.05).
Discussion
We have made several interesting findings in the present
study. First, SNI induced a marked proliferation of spinal
cord microglia in the induction phase of neuropathic pain
(day 2). Second, RTX specifically blocked the function of
nociceptive fibers without affecting propriocetive and
motor function. Third, SNI-induced microglial prolifera-
tion and p38 activation in the spinal cord was reduced by
a complete sciatic nerve blockade with bupivacaine
microspheres but not by a selective blockade of nocicep-
tive fibers with RTX. Finally, RTX blocked heat hyperalge-
sia but failed to reduce mechanical allodynia after SNI.
Microglial proliferation and activation in neuropathic pain
We found a substantial increase in the number of BrdU-
positive cells in the ipsilateral dorsal horn 2 days after
SNI. SNI-induced proliferation was restricted to Iba1-pos-
itive microglial cells. Our data are in agreement with other
studies showing microglial proliferation after sciatic nerve
transection [39] and sciatic nerve constriction [21] in rats
and partial sciatic nerve ligation in mice [40]. Prolifera-
tion of spinal astrocytes has been shown after spinal nerve
ligation in mice, using different protocol of bromodeoxy-
uridine injection [41]. Microglial activation can be
described in different ways (morphologic, specific mark-
ers or proliferation) [17]. Unfortunately, many studies
defined microglial activation only based on altered
expression of Iba1 or OX-42 (CD11b), which lead to con-
troversies when trying to link microglial activation and
pain states, because the direct role of Iba1 and CD11b in
neuropathic pain genesis is unclear. Indeed, several stud-
ies show that CD11b expression is not associated with
pain states [42-45]. Thus, it is important to use additional
markers such as ATP receptor P2X4 or active p38 MAPKMolecular Pain 2009, 5:53 http://www.molecularpain.com/content/5/1/53
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Effects of nerve block with bupivacaine microspheres (Bup, A) and resiniferatoxin (RTX, B) on heat sensitivity before and two  days after spared nerve injury (SNI) Figure 1
Effects of nerve block with bupivacaine microspheres (Bup, A) and resiniferatoxin (RTX, B) on heat sensitivity 
before and two days after spared nerve injury (SNI). Both bupivacaine and RTX increase the paw withdrawal latencies 
in injured and non injured rats. Note a decrease in latency after SNI. Baseline pain sensitivity was tested before drug treatment 
and nerve injury *p < 0.05, **p < 0.01.Molecular Pain 2009, 5:53 http://www.molecularpain.com/content/5/1/53
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Effects of nerve block with bupivacaine microspheres (Bup, A) and resiniferatoxin (RTX, B) on mechanical sensitivity before  and two days after spared nerve injury (SNI) Figure 2
Effects of nerve block with bupivacaine microspheres (Bup, A) and resiniferatoxin (RTX, B) on mechanical 
sensitivity before and two days after spared nerve injury (SNI). SNI-induced mechanical allodynia, i.e. decrease in paw 
withdrawal threshold, is not prevented by RTX treatment. Baseline pain sensitivity was tested before drug treatment and nerve 
injury *p < 0.05, **p < 0.01.Molecular Pain 2009, 5:53 http://www.molecularpain.com/content/5/1/53
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that are functionally linked to neuropathic pain develop-
ment [23,44]. We chose p-p38 as a marker of microglial
activation 2 days after SNI, since at this time point p-p38
is specifically expressed in microglia [25]. To date there is
no direct evidence that proliferation itself is necessary for
the development of neuropathic pain, but it is reasonable
to assume that an increase in the number of microglial
cells will be associated with an increase in the production
of pronociceptive mediators in microglia.
Nociceptive-specific nerve conduction block
We have shown that a complete long-term nerve block
using bupivacaine microspheres does not prevent neuro-
pathic pain development in the SNI model after initial
blockade wears off [32]. However during the period of the
transmission block, the apoptosis of dorsal horn neurons
[46] and the activation of p38 in microglia [25] are
reduced. It appears that bupivacaine microspheres only
delayed the development of pathophysiological events
leading to neuropathic pain. In contrast, Xie et al. [6] have
shown that neuropathic pain in the same model can be
prevented by application of crystallized bupivicaine to the
injury site (200 mg of a depot form bupivacaine). This dis-
crepancy may result from different duration of nerve
block. However, a complete nerve blockade for a very long
period is not practical for patients because of impaired
motor function.
TRPV1 is selectively expressed in C- and Aδ-nociceptive
fibers [27,47,48]. Clinical studies using TRPV1 antago-
nists suffer from significant side effects such as hyperther-
mia [49]. Development of TRPV1 agonist (e.g., capsaicin
or resiniferatoxin)-based pain therapy appears to be an
attractive alternative [50]. TRPV1 agonists induce desensi-
SNI induces microglial proliferation in the spinal cord Figure 3
SNI induces microglial proliferation in the spinal cord. (A) Bromodeoxyuridine (BrdU) staining in the dorsal horn of 
the spinal cord two days after SNI. There is a dramatic increase in number of BrdU-positive profiles in the dorsal horn ipsilat-
eral to nerve injury. Scale bar, 200 μm. (B-D) Enlargement of the ipsilateral medial dorsal horn (square indicated in A) showing 
co-localization of BrdU with the microglial marker Iba1. Scale bars, 50 μm.Molecular Pain 2009, 5:53 http://www.molecularpain.com/content/5/1/53
Page 9 of 14
(page number not for citation purposes)
tization and inactivation of nociceptive neurons, imped-
ing these neurons to respond to a subsequent stimulus
[28]. Recent studies have shown that activation of TRPV1
with capsaicin or lidocaine can selectivity deliver a quater-
nary local anesthetic QX-314 to target only nociceptive
fibers for a sustained blockade [26,30]. However the dura-
tion of this specific blockade (<12 h) may not be long
enough for the purpose of the present study. RTX is an
ultra potent agonist of TRPV1. Compared to capsaicin,
RTX produces a shorter period of intense excitation but a
longer period of desensitization [29]. After application of
0.01% RTX to the sciatic nerve, we found no impairment
of motor function but a blockade of heat responses in
naïve and SNI animals. However, SNI-induced tactile allo-
dynia was not affected by RTX, in agreement with a previ-
ous study showing that stimulus-evoked tactile allodynia
after nerve injury requires large Aβ-fibers [51].
Primary afferent input, microglial activation, and 
neuropathic pain
Nerve injury-induced spontaneous activity is critical for
the genesis of neuropathic pain. This spontaneous activity
is also important for the early phase of p38 activation in
spinal microglia [25] and OX-42 expression [52] in the
spinal cord. But the relative contribution of C-fibers vs A-
fibers to microglial activation remains elusive. A recent
study shows that electrical stimulation at C-fiber intensity
(10 mA, 5 min, 10 Hz) is sufficient to induce spinal Iba1
expression and mechanical allodynia without producing
nerve injury. However, microglial activation by electrical
stimulation, in the absence of nerve injury, is very mild.
Indeed specific activation of C-fibers with capsaicin fails
to activate spinal microglia [31]. Given the fact that elec-
trical stimulation at C-fiber intensity will automatically
activate A-fibers, the contribution of A-fibers to microglial
activation cannot be excluded, although activation of A-
fibers per se may not be sufficient to activate microglia.
In the spinal nerve ligation model, early ectopic activity in
the first days is seen in myelinated fibers of the injured
spinal nerve. This activity is also found in C-fibers of the
neighbouring intact spinal nerve in a later stage (several
weeks) [7,8,53,54]. However, Wu et al. reported C-fiber
activity in neighbouring intact fibers in the first day [5].
After complete transection of the sciatic nerve, C-fibers
show spontaneous activity one month after injury [55],
whereas A-fibers exhibit this activity in the first several
days [10]. Following partial sciatic transection, ectopic
bursting discharges from Aδ- and C-fibers were recorded
on post-injury day14-18 [56]. In the CCI model spontane-
ous activity is recorded primarily in myelinated fibers
[57]. Although there is a burst of discharge in C fibers
within minutes after injury, this burst fades after 15 min-
utes [12]. Therefore, spontaneous activity in early period
Confocal microscopy images show BrdU expression in spinal microglia two days after SNI Figure 4
Confocal microscopy images show BrdU expression in spinal microglia two days after SNI. (A-C) Colocalization 
of BrdU and Iba1 in the medial superficial spinal cord. Scale bars, 50 μm. (D) Stack of confocal images (2 μm apart) from a dou-
ble-labeled cell enlarged from a square in C. (E) Merge of all images in D. Scale bars, 20 μm.Molecular Pain 2009, 5:53 http://www.molecularpain.com/content/5/1/53
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Bupivacaine but not resiniferatoxin reduces cell proliferation in the spinal cord dorsal horn after SNI Figure 5
Bupivacaine but not resiniferatoxin reduces cell proliferation in the spinal cord dorsal horn after SNI. (A-D) 
BrdU immunostaining in the dorsal horn of control rats (A) and SNI rats receiving vehicle (B), RTX (C), and bupivacaine (Bup, 
D). (E) Number of BrdU-positive cell profiles in the dorsal horn: Left, effects of RTX on SNI-induced cell proliferation. Right: 
effects of bupivacaine on SNI-induced cell proliferation *p < 0.05, **p < 0.01, ns = no significance. Scale bar 200 μm. n = 3-5.Molecular Pain 2009, 5:53 http://www.molecularpain.com/content/5/1/53
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Bupivacaine but not resiniferatoxin reduces the phosphorylation of p38 MAPK in the spinal cord dorsal horn after SNI Figure 6
Bupivacaine but not resiniferatoxin reduces the phosphorylation of p38 MAPK in the spinal cord dorsal horn 
after SNI. (A-D) p-p38 immunostaining in the dorsal horn of control rats (A) and SNI rats receiving vehicle (B), RTX (C), and 
bupivacaine (Bup, D). (E) Number of p-p38-positive cell profiles in the dorsal horn: Left, effects of RTX on SNI-induced cell 
proliferation. Right: effects of bupivacaine on SNI-induced cell proliferation *p < 0.05, **p < 0.01, ns = no significance. Scale bar 
100 μm. n = 3-5.Molecular Pain 2009, 5:53 http://www.molecularpain.com/content/5/1/53
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after nerve injury is mainly fired in myelinated fibers,
despite its presence in C-fibers. Consistently, we found
that C-fibers had no role in early phase activation of
microglia and development of mechanical allodynia in
the SNI model.
Our data show that RTX fails to inhibit SNI-induced
microglial proliferation and p38 activation in the spinal
cord, suggesting that a selective nociceptive block (prima-
rily targeting C-fibers) is not sufficient to prevent micro-
glial activation. As the bupivacaine block (targeting all
fibers) significantly reduced microglial activation, we con-
clude that activity of thicker myelinated A-fibers is
required for microglial activation. However, since we are
not able to specifically block the activity of large A-fibers,
we cannot exclude a role of C-fibers in microglial activa-
tion. There are other possibilities that we should consider.
First, TRPV1 is not expressed in all nociceptive fibers and
therefore some nociceptive input could still reach to the
spinal cord. Second, the C-fiber conduction block
induced by RTX may not be complete. Third, the initial
excitation triggered by RTX or mild nerve injury induced
by RTX could induce microglial activation.
Our data also suggest that p38 activation in spinal micro-
glia is associated with the development of mechanical
allodynia but not heat hyperalgesia, because RTX blocks
heat hyperalgesia but has no effect on microglial p38 acti-
vation and mechanical allodynia after SNI. Consistently,
intrathecal injection of p38 inhibitors can effectively
reduce mechanical allodynia after nerve injury [23-25,58]
and paw incision [59]. In parallel, robust mechanical allo-
dynia is also induced after spinal injection of ATP-acti-
vated microglia [44] or following activation of microglia
by electrical stimulation [31]. In contrast, p38 activation
in primary sensory neurons in the dorsal root ganglion is
associated with the development of heat hyperalgesia by
regulating the expression of TRPV1 [27,60].
Although bupivacaine blockade significantly reduced the
microglial activation, it did not abolish the activation. The
remaining microglial activation could be triggered by
ectopic impulses arising proximally to the block, such as
DRG and dorsal root. There is also activity-independent
activation of microglia that is caused by nerve injury-
induced disruption of retrograde axonal transport [61-
64]. Glial cells may also activate each other by releasing
pro-inflammatory cytokines and chemokines.
Conclusion
We have demonstrated that microglial activation in the
spinal cord after nerve injury is associated with the devel-
opment of tactile allodynia, a cardinal feature of chronic
pain. We have also revealed that a specific nociceptive
blockade by RTX is insufficient to inhibit microglial acti-
vation and mechanical allodynia after SNI. Because bupi-
vacaine can inhibit SNI-induced microglial activation, we
conclude that spinal microglial activation after peripheral
nerve injury requires peripheral spontaneous activity from
large myelinated (Aβ/Aδ) afferent fibers, although we
should not exclude the role of small unmyelinated (C)
fibers. It is becoming obvious that major surgeries such as
thoracotomy cause high incidence of chronic pain (neuro-
pathic pain) due to possible nerve damage [1]. Given the
importance of microglial activation in the development of
neuropathic pain, the failure of nociceptive blockade to
prevent microglial activation would indicate that this
treatment will also fail to prevent the development of neu-
ropathic pain in patients with major surgeries, although
nociceptive blockade is effective to block acute pain.
Indeed, blocking peripheral activity after surgery for acute
pain relief and preventing the occurrence of chronic post-
operative pain has shown variable results [65,66]. Addi-
tional treatment such as p38 MAP kinase inhibitor is
needed to abolish or reduce microglial activation for the
prevention of neuropathic pain development.
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